Trospium Chloride Tablet, Film Coated
Product Images NDC 90096-141

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 90096-141). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zameer Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Label Tros)

Label (Label Tros)
Trozslum Chloride Tablets, USP is a drug distributed by Zameer Pharmaceuticals LLC, consisting of 60 film-coated tablets, each contains 20mg of Trospium Chloride, USP. It is important to keep this drug out of reach of children and store it within the range of 15-30°C. Dispense in tight containers as defined by USP. For further information, refer to the package insert and prescribing information.*
FDA Label Image

Fig 2 (Draft Labeling 1)

Fig 2 (Draft Labeling 1)
FDA Label Image

Table 4 (Draft Labeling 10)

Table 4 (Draft Labeling 10)
Table 4 shows the efficacy of Trospium chloride tablets in comparison to Placebo for urinary frequency, urge incontinence episodes, and void volume in Study 2. The table displays the mean change from baseline to week 12 or last observation carried forward (LOCF) for each endpoint. The treatment differences were assessed by analysis of variance for ITTLOCF data set for urinary frequency and urinary void volume, and by ranked analysis of variance for ITTLOCE data set for urge incontinence episodes. Trospium chloride tablets showed a statistically significant reduction in urinary frequency and urge incontinence episodes compared to placebo. The mean change from baseline for Trospium chloride tablets was -27(02) for urinary frequency, -161(10) for urge incontinence episodes, and 356 (28) for urinary void volume. The values in the table are reported as Mean (SE) and P-values are also provided.*
FDA Label Image

Fig 3 (Draft Labeling 2)

Fig 3 (Draft Labeling 2)
FDA Label Image

Fig 4 (Draft Labeling 3)

Fig 4 (Draft Labeling 3)
FDA Label Image

Fig 5 (Draft Labeling 4)

Fig 5 (Draft Labeling 4)
FDA Label Image

Structure (Draft Labeling 6)

Structure (Draft Labeling 6)
FDA Label Image

Table 1 (Draft Labeling 7)

Table 1 (Draft Labeling 7)
This is a table showing the adverse reactions experienced by patients taking Trospium chloride tablets 20 mg twice a day. The reactions are divided into different categories. The most common adverse reactions reported were dry mouth and constipation. Other adverse reactions reported include abdominal pain, dyspepsia, headache, fatigue, urinary retention and dry eyes. The numbers between the brackets indicate the percentage of patients who experienced each adverse reaction. The numbers outside the brackets indicate the number of patients who experienced each adverse reaction. The price of the tablets is also included (¥=590).*
FDA Label Image

Table 2 (Draft Labeling 8)

Table 2 (Draft Labeling 8)
This is a pharmacokinetic parameter estimates table for 20mg Trospium Chloride tablets in Healthy Volunteers. The table includes the mean and standard deviation values for AUCp and Tax. However, the units used for the values are not clear due to the poor quality of .*
FDA Label Image

Table 3 (Draft Labeling 9)

Table 3 (Draft Labeling 9)
Table 3 shows the mean change from baseline to the end of treatment in Study 1 for urinary frequency, urge incontinence episodes, and void volume. The data indicates a significant improvement for patients taking Trospium chloride tablets compared to those taking a placebo. Treatment differences were assessed by analysis of variance for ITTLOCE data set.*
FDA Label Image

Fig 1 (Draft Labeling)

Fig 1 (Draft Labeling)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.